On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome

This article has no abstract
Epistemonikos ID: 9cac1b91bf4953b4b3e283f603d50756a540018a
First added on: Feb 11, 2025